<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/20/helix-biopharma-otcmktshbpcf-shares-down-1-9.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-20T12:30:40+00:00"/>
    <meta property="og:title" content="Helix Biopharma (OTCMKTS:HBPCF) Shares Down 1.9%"/>
    <meta property="og:description" content="Helix Biopharma Corp. (OTCMKTS:HBPCF) was down 1.9% during mid-day trading on Monday . The stock traded as low as $0.85 and last traded at $0.85, approximately 650 shares traded hands during mid-day trading. An increase of 1,900% from the average daily volume of 33 shares. The stock had previously closed at $0.87. The firm has [â€¦]"/>
  </head>
  <body>
    <article>
      <h1>Helix Biopharma (OTCMKTS:HBPCF) Shares Down 1.9%</h1>
      <address><time datetime="2019-11-20T12:30:40+00:00">20 Nov 2019, 12:30</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>Helix Biopharma Corp. (OTCMKTS:HBPCF) was down 1.9% during mid-day trading on Monday . The stock traded as low as $0.85 and last traded at $0.85, approximately 650 shares traded hands during mid-day trading. An increase of 1,900% from the average daily volume of 33 shares. The stock had previously closed at $0.87.</p>
      <p>The firm has a fifty day moving average of $0.85 and a 200-day moving average of $0.51.</p>
      <p>Helix Biopharma (OTCMKTS:HBPCF) last posted its quarterly earnings results on Friday, October 25th. The company reported ($0.02) earnings per share (EPS) for the quarter.</p>
      <p><b>Helix Biopharma Company Profile</b> (<a href="https://www.marketbeat.com/stocks/OTCMKTS/HBPCF/">OTCMKTS:HBPCF</a>)</p>
      <p>Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. The company is developing L-DOS47 for the treatment of non-squamous small cell lung cancer, as well as for colon, pancreas, and breast cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/market-data/52-week-lows/">What is the 52-week high/low?</a></p>
    </article>
  </body>
</html>